Medivir has agreed to sell its commercial unit to Karo Pharma for SEK 908 million ($101 million) in cash. The deal pushes forward Medivir’s plan to shed its established drugs and emerge as an oncology-focused biotech.
Stockholm, Sweden-based Medivir committed to splitting its commercial and R&D units in August. At the time, the commercial business was expected to operate as a standalone company and list on the local stock exchange. Medivir rethought that plan after news of the split brought forward companies interested in buying the commercial unit. And, with Karo’s offer proving more tempting than going solo, Medivir has decided to sell up rather than list the business.
The deal, which is expected to close in December, frees Medivir from the specialty pharma business it bought in 2011 and returns it to its biotech roots. Those roots run deep. Medivir spun out of Astra, now AstraZeneca, in 1988 and formed pacts with Bristol-Myers Squibb, Eli Lilly, Johnson & Johnson and Roche down the years. But it is now some time since its pipeline has generated considerable excitement.
Medivir is looking to its rebirth as a pure-play biotech to revive its fortunes. The company outlined its plans for the next chapter of its history last month when it axed 30 jobs as part of a retreat from early-stage research and infectious diseases, its historic area of specialization. Medivir 2.0 is focused on cancers including hepatocellular carcinoma, an indication in which it thinks its experience delivering drugs to the liver to treat hepatitis B and C gives it a foothold.
In doubling down on R&D, Medivir has taken the opposite path from the buyer of its commercial unit. Karo once sat alongside Medivir on the list of promising Swedish biotechs having landed deals with Merck and Pfizer. But in recent years it has shifted gears, gradually offloading its pipeline programs while buying itself a portfolio of commercial assets. The deal with Medivir adds another 13 products to its roster.
By Nick Paul Taylor
Source: Fierce Biotech
Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.
Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.
On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.
